551 Targeting the Redox Vulnerability of V600E BRAF-mutated Malignant Melanoma Cells Using the Electron Transfer Reactant PMS (Phenazine Methosulfate) as a Mitochondria-Directed Chemotherapeutic

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2016.02.589
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Metformin Accelerates the Growth of BRAF V600E -Driven Melanoma by Upregulating VEGF-A

Cancer Discovery
Oncology
2012English

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Dermatology Research and Practice
Dermatology
2012English

Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology
Cancer ResearchOncology
2018English

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Clinical Cancer Research
Cancer ResearchOncology
2019English

LETTER TO THE EDITOR: Management of Vemurafenib Induced Severe Arthralgia and Pyrexia in a Patient With BRAF V600E Mutated Melanoma: First Experience With a Switch to Dabrafenib

Open Dermatology Journal
Dermatology
2015English

OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib

PLoS ONE
Multidisciplinary
2013English

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy